ALGBE Fundamental Analysis - GLOBAL BIOENERGIES SA

Fundamental Rating

ALGBE gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 74 industry peers in the Chemicals industry. ALGBE may be in some trouble as it scores bad on both profitability and health. ALGBE has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ALGBE has reported negative net income.

ALGBE had a negative operating cash flow in the past year.

In the past 5 years ALGBE always reported negative net income.

In the past 5 years ALGBE always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -60.73%, ALGBE is doing worse than 94.59% of the companies in the same industry.

Looking at the Return On Equity, with a value of -346.31%, ALGBE is doing worse than 93.24% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-60.73%
ROE	-346.31%
ROIC	N/A

ROA(3y)-54.57%

ROA(5y)-48.79%

ROE(3y)-195.4%

ROE(5y)-183.82%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ALGBE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALGBE does not have a ROIC to compare to the WACC, probably because it is not profitable.

ALGBE has about the same amout of shares outstanding than it did 1 year ago.

Compared to 5 years ago, ALGBE has more shares outstanding

ALGBE has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -2.52, we must say that ALGBE is in the distress zone and has some risk of bankruptcy.

With a Altman-Z score value of -2.52, ALGBE is not doing good in the industry: 90.54% of the companies in the same industry are doing better.

ALGBE has a Debt/Equity ratio of 2.78. This is a high value indicating a heavy dependency on external financing.

The Debt to Equity ratio of ALGBE (2.78) is worse than 93.24% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	2.78
Debt/FCF	N/A
Altman-Z	-2.52

ROIC/WACCN/A

WACC4.52%

2.3 Liquidity

ALGBE has a Current Ratio of 2.86. This indicates that ALGBE is financially healthy and has no problem in meeting its short term obligations.

Looking at the Current ratio, with a value of 2.86, ALGBE belongs to the top of the industry, outperforming 82.43% of the companies in the same industry.

ALGBE has a Quick Ratio of 2.73. This indicates that ALGBE is financially healthy and has no problem in meeting its short term obligations.

ALGBE has a Quick ratio of 2.73. This is amongst the best in the industry. ALGBE outperforms 93.24% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.86
Quick Ratio	2.73

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ALGBE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.31%, which is quite impressive.

The Revenue for ALGBE has decreased by -88.90% in the past year. This is quite bad

Measured over the past years, ALGBE shows a very strong growth in Revenue. The Revenue has been growing by 25.15% on average per year.

EPS 1Y (TTM)33.31%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%33.52%

Revenue 1Y (TTM)-88.9%

Revenue growth 3Y52.9%

Revenue growth 5Y25.15%

Sales Q2Q%-85.13%

3.2 Future

The Earnings Per Share is expected to decrease by -5.13% on average over the next years.

Based on estimates for the next years, ALGBE will show a small growth in Revenue. The Revenue will grow by 0.48% on average per year.

EPS Next Y22.81%

EPS Next 2Y-5.13%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year0.97%

Revenue Next 2Y0.48%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ALGBE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year ALGBE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as ALGBE's earnings are expected to decrease with -5.13% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-5.13%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ALGBE!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

GLOBAL BIOENERGIES SA

EPA:ALGBE (11/28/2025, 7:00:00 PM)

0.0185

0 (-7.5%)

Chartmill FA Rating

GICS SectorMaterials

GICS IndustryGroupMaterials

GICS IndustryChemicals

Earnings (Last)10-01 2025-10-01

Earnings (Next)02-02 2026-02-02/amc

Inst Owners1.07%

Inst Owner ChangeN/A

Ins Owners2.68%

Ins Owner ChangeN/A

Market Cap336.14K

Revenue(TTM)360.60K

Net Income(TTM)-5.86M

Analysts84.44

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.93
P/FCF	N/A
P/OCF	N/A
P/B	0.2
P/tB	0.21
EV/EBITDA	N/A

EPS(TTM)-0.32

EYN/A

EPS(NY)-0.23

Fwd EYN/A

FCF(TTM)-0.44

FCFYN/A

OCF(TTM)-0.41

OCFYN/A

SpS0.02

BVpS0.09

TBVpS0.09

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-60.73%
ROE	-346.31%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-54.57%

ROA(5y)-48.79%

ROE(3y)-195.4%

ROE(5y)-183.82%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score0

Asset Turnover0.04

Health

		Industry Rank	Sector Rank
Debt/Equity	2.78
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	18.66%
Cap/Sales	129.34%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.86
Quick Ratio	2.73
Altman-Z	-2.52

F-Score0

WACC4.52%

ROIC/WACCN/A

Cap/Depr(3y)101.02%

Cap/Depr(5y)112%

Cap/Sales(3y)139.76%

Cap/Sales(5y)838.08%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)33.31%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%33.52%

EPS Next Y22.81%

EPS Next 2Y-5.13%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-88.9%

Revenue growth 3Y52.9%

Revenue growth 5Y25.15%

Sales Q2Q%-85.13%

Revenue Next Year0.97%

Revenue Next 2Y0.48%

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y29.69%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year29.13%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y3.08%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y4.94%

OCF growth 3YN/A

OCF growth 5YN/A

GLOBAL BIOENERGIES SA / ALGBE.PA FAQ

What is the fundamental rating for ALGBE stock?

ChartMill assigns a fundamental rating of 2 / 10 to ALGBE.PA.

What is the valuation status for ALGBE stock?

ChartMill assigns a valuation rating of 0 / 10 to GLOBAL BIOENERGIES SA (ALGBE.PA). This can be considered as Overvalued.

How profitable is GLOBAL BIOENERGIES SA (ALGBE.PA) stock?

GLOBAL BIOENERGIES SA (ALGBE.PA) has a profitability rating of 0 / 10.

What is the earnings growth outlook for GLOBAL BIOENERGIES SA?

The Earnings per Share (EPS) of GLOBAL BIOENERGIES SA (ALGBE.PA) is expected to grow by 22.81% in the next year.

GLOBAL BIOENERGIES SA (ALGBE.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

GLOBAL BIOENERGIES SA / ALGBE.PA FAQ

What is the fundamental rating for ALGBE stock?

What is the valuation status for ALGBE stock?

How profitable is GLOBAL BIOENERGIES SA (ALGBE.PA) stock?

What is the earnings growth outlook for GLOBAL BIOENERGIES SA?